QUDEXY XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUDEXY XR (QUDEXY XR).
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
| Metabolism | Primarily hepatic via CYP3A4; also undergoes hydrolysis to carbamazepine epoxide (active metabolite) and further glucuronidation. |
| Excretion | Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%). |
| Half-life | Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks). |
| Protein binding | Protein binding is 13-17% (primarily to albumin); low binding minimizes displacement interactions. |
| Volume of Distribution | Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution primarily in total body water. |
| Bioavailability | Oral bioavailability is approximately 100% for the extended-release formulation; food does not affect absorption. |
| Onset of Action | Oral: onset of seizure reduction typically observed within 1-2 weeks of therapeutic dosing; maximal effect may require 4-8 weeks. |
| Duration of Action | Duration of action is approximately 12 hours; twice-daily dosing maintains therapeutic concentrations; missed doses may increase seizure risk. |
| Molecular Weight | 339.4 |
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl 30-49 mL/min: reduce by 50%. CrCl <30 mL/min: not recommended. Hemodialysis: supplemental dose of 50-100 mg after each dialysis session. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: contraindicated. |
| Pediatric use | Ages 2-17: initial 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target 200-400 mg/day in two divided doses. Weight-based not required; use same dose as adults. |
| Geriatric use | Start at 25 mg orally twice daily; consider slower titration due to age-related renal decline. Monitor renal function and adjust per CrCl. |
| 1st trimester | Increased risk of major congenital malformations, particularly neural tube defects, cleft lip/palate, and cardiac defects. Use only if benefit justifies risk. |
| 2nd trimester | Risk of neurodevelopmental delay and reduced IQ in offspring. Increased risk of hemorrhagic complications in newborns. Use only if benefit justifies risk. |
| 3rd trimester | Risk of neonatal hemorrhage, hypocalcemia, hypoglycemia, and respiratory depression. Withdrawal symptoms may occur. Use only if benefit justifies risk. |
Clinical note
Comprehensive clinical and safety monograph for QUDEXY XR (QUDEXY XR).
| Placental transfer | Crosses the placenta readily; fetal plasma levels similar to maternal. |
| Breastfeeding | Topiramate is excreted into human milk at concentrations similar to maternal plasma. Monitor infant for drowsiness, poor feeding, and diarrhea. Benefit of breastfeeding should be weighed against potential risks. |
■ FDA Black Box Warning
QUDEXY XR is associated with an increased risk of suicidal thoughts or behavior in patients taking antiepileptic drugs. Monitor for emergence or worsening of depression, suicidal thoughts, or unusual changes in mood or behavior.
| Serious Effects |
Hypersensitivity to topiramate or any componentRecent alcohol use (within 6 hours)Concomitant use with carbonic anhydrase inhibitors (e.g., acetazolamide) due to increased risk of kidney stones and metabolic acidosis
| Precautions | Suicidal behavior and ideation; serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis); multi-organ hypersensitivity reactions; decreased serum sodium; hepatotoxicity; hematologic effects (aplastic anemia, agranulocytosis); dizziness, somnolence, ataxia; withdrawal seizures; ophthalmic effects (pupillary defects, blurred vision); interaction with oral contraceptives; use in pregnancy (fetal harm); interaction with other drugs (e.g., CNS depressants, MAOIs). |
| Food/Dietary | Grapefruit juice may reduce topiramate systemic exposure by inhibiting OATP1A2 and CYP3A4, potentially decreasing efficacy. Avoid concurrent intake of high-fat meals as they may delay absorption but not affect overall bioavailability. Maintain consistent dietary habits to minimize fluctuations in absorption. No other significant food interactions reported. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Topiramate is associated with an increased risk of oral clefts (cleft lip with or without cleft palate) in infants exposed during the first trimester. The risk is dose-dependent, with higher doses (>200 mg/day) conferring greater risk. In the second and third trimesters, topiramate exposure may be associated with reduced fetal growth and low birth weight. Topiramate is pregnancy category D (positive evidence of human fetal risk). |
| Fetal Monitoring | Women of childbearing potential should be counseled about the risks of topiramate during pregnancy and the use of effective contraception. If pregnancy occurs, prenatal monitoring should include high-resolution ultrasound to detect oral clefts (typically at 18-20 weeks gestation). Monitor fetal growth throughout pregnancy. Neonates should be monitored for withdrawal symptoms (hyperexcitability, irritability) after birth. |
| Fertility Effects | Topiramate may affect fertility. In women, it can disrupt the hypothalamic-pituitary-ovarian axis, leading to menstrual irregularities, anovulation, and decreased fertility. In men, topiramate has been associated with decreased sperm count and motility in animal studies; human data are limited. Reversible upon discontinuation. |
| Clinical Pearls | Qudexy XR is a topiramate extended-release formulation. To reduce nephrolithiasis risk, maintain adequate hydration. Avoid concurrent use with carbonic anhydrase inhibitors (e.g., acetazolamide) as they increase stone risk. Monitor serum bicarbonate for metabolic acidosis, especially in patients with predisposing conditions. Titrate slowly to mitigate CNS effects like cognitive slowing. Effective for migraine prophylaxis and epilepsy; adjust dose in renal impairment. Avoid abrupt discontinuation to prevent seizure rebound. |
| Patient Advice | Swallow capsules whole; do not crush or chew. · May cause dizziness, drowsiness, or blurred vision; avoid driving until effects are known. · Drink plenty of fluids to reduce kidney stone risk. · Report symptoms of metabolic acidosis: fatigue, rapid breathing, confusion. · Do not stop taking suddenly; withdrawal may trigger seizures. · Use effective contraception as topiramate can reduce oral contraceptive efficacy. · Inform your doctor of all medications, especially carbonic anhydrase inhibitors or other topiramate products. · Avoid alcohol as it may worsen CNS depression. |